此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)

2026年8月18日 更新者:Marshall Holland

Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)

This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.

研究概览

详细说明

Restless Legs Syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs that disrupts sleep and quality of life. Current medical therapies often lose effectiveness over time or are associated with significant side effects. Preliminary case reports suggest that spinal cord stimulation (SCS) may improve RLS symptoms.

This single-arm feasibility study will enroll up to 15 adults with severe, treatment-refractory primary RLS. Participants will undergo baseline clinical, neuropsychological, and electrophysiological assessments followed by implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System. Follow-up evaluations will occur through 24 months post-activation. Primary outcomes focus on device and procedure safety. Secondary outcomes evaluate changes in RLS severity, patient-reported outcomes, neurophysiological biomarkers, and device utilization.

研究类型

介入性

注册 (估计的)

15

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35233

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Age >18 years and older.
  2. Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire.
  3. IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician.
  4. RLS symptoms occur ≥ 3 nights per week.
  5. Willing and able to comply with study procedures.
  6. Able to provide informed consent.

Exclusion Criteria:

  1. Age <18 years.
  2. Neuropathic pain, other than RLS on DN4 questionnaire.
  3. Any mental or physical limitation that would prevent completing and of the study protocols.
  4. Active medical implant in the body (i.e., pacemaker).
  5. History of prior SCS trial or implantation.
  6. Currently using another device to treat RLS.
  7. Unable or unwilling to comply with study protocols.
  8. Other medical conditions that would put the subject at risk as determined by the investigators.
  9. Pregnant, breastfeeding, or trying to become pregnant.
  10. Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS.
  11. Ferritin < 50 ng/mL (excludes iron deficiency).
  12. HgA1C > 7.5 (excludes unstable diabetes melilitus)
  13. One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:SCS Implant
Implantation of the FDA-approved Saluda Medical Evoke® Spinal Cord Stimulation System with Smartloop® Technology. Two percutaneous epidural leads will be implanted in the thoracic spine (T7-T10 region) and programmed to provide chronic spinal cord stimulation for treatment of severe RLS symptoms.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and Adverse Events
大体时间:Baseline through 24 months
Frequency, severity, and relationship of device-, stimulation-, and procedure-related adverse events.
Baseline through 24 months

次要结果测量

结果测量
措施说明
大体时间
Change in International Restless Legs Syndrome Scale (IRLS)
大体时间:Baseline through 24 months
The IRLS is a validated 10-item patient-reported measure of Restless Legs Syndrome severity. Scores range from 0 to 40, with higher scores indicating worse symptom severity. A decrease in score from baseline indicates improvement.
Baseline through 24 months
Clinician Global Impression Improvement Scale (CGI-I)
大体时间:Baseline through 24 months
Baseline through 24 months
Patient Global Impression of Improvement (PGI-I)
大体时间:Baseline through 24 months
The PGI-I is a patient-reported global rating of change in symptoms and overall condition following treatment. Scores range from 1 to 7, where 1 = Very much improved and 7 = Very much worse. Lower scores represent a better outcome and greater perceived improvement.
Baseline through 24 months
Suggested Immobilization Test (SIT)
大体时间:Baseline through 24 months
Baseline through 24 months
PROMIS Sleep, Pain, Anxiety, Depression, Cognition, and Health Measures
大体时间:Baseline through 24 months
Baseline through 24 months
Changes in Neurophysiological Measures of Spinal Cord Stimulation Response
大体时间:Baseline through 24 months
Changes in H-reflexes, somatosensory evoked potentials (SSEPs), EEG measures, and device-recorded ECAPs.
Baseline through 24 months
Patient-Reported Outcomes Measurement Information System - Sleep
大体时间:Baseline through 24 months
Questionnaire assessing perceived sleep quality and difficulty falling asleep during the previous 7 days. Responses are converted to PROMIS standardized T-scores. Higher scores indicate greater sleep disturbance and a worse outcome. The T-score range is approximately 20 to 80
Baseline through 24 months
Patient-Reported Outcomes Measurement Information System - Pain
大体时间:Baseline through 24 months
Questionnaire assessing the impact of pain on daily activities and sleep during the previous 7 days. Responses are converted to PROMIS standardized T-scores. Higher scores indicate greater pain interference and a worse outcome. The T-score range is approximately 30 to 80
Baseline through 24 months
Patient-Reported Outcomes Measurement Information System - Anxiety
大体时间:Baseline through 24 months
Questionnaire assessing fear, anxious mood, and anxiety-related symptoms during the previous 7 days. Responses are converted to PROMIS standardized T-scores. Higher scores indicate greater anxiety and a worse outcome. The T-score range is approximately 40 to 85.
Baseline through 24 months
Patient-Reported Outcomes Measurement Information System - Depression
大体时间:Baseline through 24 months
Questionnaire assessing depressive symptoms, negative mood, and diminished self-worth during the previous 7 days. Responses are converted to PROMIS standardized T-scores. Higher scores indicate greater depressive symptom burden and a worse outcome. The T-score range is approximately 40 to 85.
Baseline through 24 months
Patient-Reported Outcomes Measurement Information System - Cognition
大体时间:Baseline through 24 months
Questionnaire assessing perceived cognitive abilities including memory, concentration, and mental acuity. Responses are converted to PROMIS standardized T-scores . Higher scores indicate better cognitive functioning and a better outcome. The T-score range is approximately 20 to 80.
Baseline through 24 months
Patient-Reported Outcomes Measurement Information System - Mental health battery
大体时间:Baseline through 24 months
Assesses overall mental health. Responses are converted to PROMIS standardized T-scores. Higher scores indicate better overall health status and a better outcome. T-score range is approximately 20 to 80
Baseline through 24 months
Patient-Reported Outcomes Measurement Information System - Physical Health Battery
大体时间:Baseline through 24 months
Assesses Overall Physical Health. Responses are converted to PROMIS standardized T-scores. Higher scores indicate better overall health status and a better outcome. T-score range is approximately 20 to 80
Baseline through 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Marshall Holland, MD、University of Alabama at Birmingham

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2033年10月1日

研究完成 (估计的)

2034年10月1日

研究注册日期

首次提交

2026年8月7日

首先提交符合 QC 标准的

2026年8月18日

首次发布 (实际的)

2026年8月21日

研究记录更新

最后更新发布 (实际的)

2026年8月21日

上次提交的符合 QC 标准的更新

2026年8月18日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅